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Abstract
Background: Medium-chain triglyceride (MCT) enriched diet has a positive effect on
seizure control and behavior in some dogs with idiopathic epilepsy (IE).
Objective: To evaluate the short-term efficacy of MCTs administered as an add-on
dietary supplement (DS) to a variable base diet to assess seizure control and anti-
seizure drug's (ASD) adverse effect profiles.
Animals: Twenty-eight dogs with International Veterinary Epilepsy Task Force Tier II
(IVETF) level diagnosis of treated IE with 3 or more seizures in the last 3 months
were used.
Methods: A 6-month multicenter, prospective, randomized, double-blinded, placebo-
controlled crossover trial was completed, comparing an MCT-DS with a control-DS. A
9% metabolic energy-based amount of MCT or control oil was supplemented to the
dogs' diet for 3 months, followed by a control oil or MCT for another 3 months, respec-
tively. Dogs enrolled in this study satisfied most requirements of IE diagnosis stated by
the IVETF II level. If they received an oil DS or drugs that could influence the metabo-
lism of the investigated DS or chronic ASD, the chronic ASD medication was adjusted,
or other causes of epilepsy were found, the dogs were excluded from the study.
Abbreviations: ASD, antiseizure drug; BHB, beta hydroxybutyric acid; C10, decanoic acid = capric acid; C8, octanoic acid = caprylic acid; DS, dietary supplement; IE, idiopathic epilepsy; ITTA,
intention to treat analysis; IVETF II, International Veterinary Epilepsy Task Force Tier II; KBr, potassium bromide; LEV, levetiracetam; MBW, metabolic body weight; MCT, medium-chain
triacylglyceride; ME, metabolic energy; PB, phenobarbital; QoL, quality of life; RER, resting energy requirement; RVC, Royal Veterinary College; VAS, visual analog score.
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Results: Seizure frequency (median 2.51/month [0-6.67] versus 2.67/month
[0-10.45]; P = .02) and seizure-day frequency were significantly (1.68/month [0-5.60]
versus 1.99/month [0-7.42], P = .01) lower when dogs were fed MCT-DS in compari-
son with the control-DS. Two dogs were free of seizures, 3 had ≥50% and 12 had
<50% reductions in seizure frequency, and 11 dogs showed no change or an increase
in seizure frequency.
Conclusions and Clinical Importance: These data show antiseizure properties of an
MCT-DS compared to a control oil and support former evidence for the efficacy of
MCTs as a nutritive, management option for a subpopulation of drug-resistant dogs
with epilepsy.
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1 | INTRODUCTION
Seizures and epilepsy are the most common neurological signs in dogs
affecting an estimated 0.6%-0.8%1-3 of the population. The various cellu-
lar pathophysiological mechanisms leading to epilepsy, characterized by
unprovoked recurrent seizures, remain poorly understood. As a result, the
enduring predisposition of having epileptic seizures can only be managed
by medication for seizure suppression4 (antiseizure), instead of prevention
of epilepsy5,6 (antiepileptogenic). However, the chronic administration of
antiseizure drugs (ASDs) presents difficulties in the balance between the
beneficial seizure-suppressive effects and undesirable drug-related
adverse effects.7 Around one-third of dogs continue to seizure despite
appropriately managed polypharmacotherapy.8-10 In addition, behavioral
and cognitive comorbidities occur in dogs with epilepsy,11 such as anxi-
ety12,13 deficits in spatial memory,14 or cognitive function.15,16 Seizures,
drug-related adverse effects along with changes to behavior and cogni-
tive capabilities all contribute to the reduction in quality of life (QoL) for
both dogs and their owners.17-21 Hence, new treatment strategies should
address all aspects of epilepsy to improve the overall welfare of dogs and
their owners.
Manipulation of nutrition has attracted increasing considerations
as an alternative approach to impacting seizure activity and behav-
ior.22-24 A cross-sectional study revealed that over 60% of owners
changed their dog's diet, after being diagnosed with idiopathic epi-
lepsy (IE) in an attempt to improve seizure control and protect their
dog from ASD-related adverse effects.25 The influence of dietary
modification on seizure control has been extensively studied in human
medicine26-29 and rodent epilepsy models,30-33 showing antiseizure
effects to varying degrees. Similarly, there are effects of nutritional
management and diets in dogs with epilepsy23,24,34-39 and paroxysmal
dyskinesia.40-43
A 6-month prospective, randomized, double-blinded, placebo-
controlled crossover dietary trial comparing a medium-chain triacy-
lglyceride (MCT) kibble diet (10% of the total formula calories from
octanoic acid [C8], decanoic acid [C10], lauric acid [C12]) to a standard-
ized placebo diet was completed in 21 chronically ASD-treated dogs with
IE (Figure 1).24 Consumption of a MCT diet resulted in statistically signifi-
cant elevation of serum beta hydroxybutyric acid (BHB) concentrations
and improvement in both seizure control24 and behavioral com-
orbidities.23 Although many owners add oil supplements or change their
dogs' diet,25 it is currently unknown whether a MCT oil supplement might
possess similar beneficial effects.24
The study hypothesis for the current study was that dietary sup-
plementation with a commercially available MCT oil would reduce sei-
zure frequency in dogs with IE and be well tolerated. Therefore, the
aims of this clinical study were to investigate antiseizure effects and
tolerability of MCT dietary supplement (MCT-DS) in dogs with IE
compared with a standardized control-DS.
2 | MATERIAL AND METHODS
This study was conducted in accordance with the guidelines of the
International Cooperation of Harmonization of Technical Requirements
for Registration of Veterinary Products GL9 Good Clinical Practices and
the European Agency for the evaluation of Medical Products. This
study was approved by the Royal Veterinary College (RVC) Clinical
Research Ethical Review Board and ethical approval was granted (URN
2016 1558).
2.1 | Study design
The study design has been published separately.44 In brief, the main
study hypothesis was that MCTs administered as a DS would reduce
seizure frequency. Thus, altered seizure frequency will serve as primary,
measurable outcome variable to assess therapeutic effect. Changes in
ASD adverse effects and quality of life of dogs with IE were assessed as
a secondary outcome.
Based on the former research conducted 22 dogs completing the
trial appeared sufficient to reach significance between groups.24,38 A
retrospective power analysis based on the former results of reducing
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seizure frequency when fed a MCT diet from 2.67 to 2.31/month in
comparison with the placebo diet indicated that 22 dogs would be
sufficient to reach a power of 0.95 (95%) at type I error rate of 0.05
(PASS V19.02, NCSS, Statistical Software, Kaysville, Utah). Consider-
ing in addition the usual dropout rate of around 30%, the aim was to
recruit 36 dogs.
The study involved a 6-month prospective, randomized, double-
blinded, placebo-controlled, multicenter dietary crossover trial compar-
ing the MCT-DS to a standardized control oil DS for canine epilepsy. As
a multicenter study, dogs were recruited over 6 study sites (Germany
[Mannheim, Cologne, Hannover], Finland [Helsinki], United Kingdom
[London, Derby]). Dogs enrolled onto this study were fed for 3 months
(day 1 to day 90 ± 2) initially with either control-DS or MCT-DS along-
side their normal diet, followed by a respective switch for another
3 months (day 90 to day 187 ± 2) to the other supplement alongside
their normal diet. The first 7 days of dietary crossover, DS period 2 (day
90 to day 97 ± 2), were excluded from data collection and considered
as the wash-out period. Dogs were fed twice per day when each feed
was supplemented with the respective DS-oil representing 4.5% daily
metabolic energy requirement for each dog (total 9% of metabolic
energy [ME]). The DS allocations were block-randomized and only avail-
able to the study nurse who was also the DS dispenser based at clinical
investigation center at the RVC. Dog owners, investigators, other
nurses, and statisticians involved were blinded throughout the study.
ASD treatment was not altered by any person involved at any point
in this study. Per visit all dogs were evaluated on-site. On each study
visit relevant data were collected at the enrolment visit and start of the
study (V1 = day 0), and at the end of each dietary intervention period
(V2 = 90 ± 2 days, V3 = 187 ± 2 days) including general physical and
neurological examination, seizure frequency (only generalized tonic-
clonic seizures were recorded); body weight; measurements of serum
phenobarbital (PB), potassium bromide (KBr), or both concentrations as
appropriate; dynamic bile acids; CBC; standard clinical serum chemistry;
canine pancreatic lipase activity; adverse events; and visual analog
scores (VAS) for ataxia, sedation, and QoL. Behavioral comorbidities
and cognition have been measured but will be reported separately.
2.2 | Dietary supplements
The experimental control and test products were commercially available
DSs suitable for human consumption. The test oil was a MCT-DS puri-
fied from palm and rapeseed oil containing 50%-65% octanoic acid
(C8) and 30%-50% decanoic acid (C10) with 8.37 kcal/mL from 93%
saturated fatty acids (End GmbH, Germany, Batch No. L 16M12). The
control oil was colorless, extra-virgin olive oil with 8 kcal per ml con-
taining 11% saturated, 11% polyunsaturated, and 78% monounsatu-
rated fat (Filippo Berio, Italy, Batch No LE194M04). Both oils were
dispensed in brown bottles ensuring blinding of all involved. Prior to
study setup, both oil supplements have been tested in a small cohort of
healthy nonepileptic dogs (n = 19) on palatability, preference, side
effects, and eating behavior confirming comparability.
The control and the MCT oil were stored at room temperature in a
locked room at each test site. Owners were educated to keep the base
diet consistent throughout the study. The quantity of DS-oil given daily
was calculated according to the metabolic weight, age, and neuter
F IGURE 1 CONSORT flow
diagram: flow diagram of the progress
through the phases of this randomized
clinical trial of 2 groups (ie, enrolment,
intervention allocation, follow-up, and
data analysis)
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status of each dog individually and represented 9% isoenergetic
requirement per day. The base diet was recorded, but not individually
checked to fulfill nutritional requirements. A deviation of ±10% of the
base diet consumption (kg) was allowed taking into consideration differ-
ences in activity level, physical condition, and to prevent gain or loss of
body weight.
2.3 | Case selection
Dogs were recruited by a 2-step screening system through different
media in the United Kingdom and Europe. An online prestudy question-
naire (SurveyMonkey) was completed for each dog, capturing all rele-
vant data of epilepsy phenotype. Dogs were enrolled only when level
of IE diagnosis45 satisfied most requirements stated by the International
Veterinary Epilepsy Task Force Tier II IE diagnosis. Inclusion criteria
required for enrolment onto this study were: age of seizure onset
between 6 months and ≤12 years; weighing between 4 and ≤65 kg;
unremarkable interictal neurological examinations for a dog on ASD; no
clinically significant findings on CBC, unremarkable serum biochemistry,
and dynamic bile acid results; unremarkable former cerebrospinal fluid
analysis and magnetic resonance imaging scan; have had at least 3 gen-
eralized seizure episodes in the previous 3 months prior to enrolment;
treated with at least 1 ASD and being classified as resistant to at least
1 of the ASD(s) given6 by responding with less than 50% reduction in
seizure frequency. Dogs were excluded if they received an oil DS or
drugs that could influence the metabolism of the investigated DS or
chronic ASD. Dogs with other causes of epilepsy such as brain neo-
plasm, brain trauma, encephalitis, and meningitis; with chronic or acute
renal, hepatic or cardiac disease; clinical history of pancreatitis or
pancreatic insufficiency (exocrine pancreatic insufficiency, diabetes
mellitus); with an acute or surgical condition at the time of enrolment;
and bitches known or suspected to be pregnant or lactating were all
excluded from the study. Dogs were enrolled as an individual experi-
mental unit, and only 1 dog per household were enrolled onto this
study. A unique study case number, consisting of a 3-digit number
(study side number-study case number), ascending in a chronological
order of enrolment, was assigned and used to identify each dog
throughout the study. In total, 36 dogs were recruited onto this study.
3 | SEIZURE DATA
Information from a standardized seizure diary per dietary intervention
period was used to assess the short-term effects of MCT-DS on seizure
control.44 At each study visit, the owners were repeatedly instructed,
how to complete the seizure diary and each listed seizure event has
been reevaluated by the owner's description. Only generalized seizures
were counted toward the efficacy measurement and the primary out-
come variable is the change of seizure frequency. Therapeutic success
was defined as a significant difference (reduction) in 1 of seizure fre-
quency (seizures/month), seizure days frequency per months, seizure
cluster days frequency per months, seizure severity measured by
number of episodes of cluster seizures or status epilepticus during a
3-month period between the MCT, and control periods. Finally, each
dog will be classified as a “MCT responder” if it experiences at least
50% reduction in seizure frequency between both dietary periods.
3.1 | Visual analog score
Visual analog score for ataxia, sedation and overall QoL was completed by
the owner at each study visit. The owner was asked to mark a measure-
ment line ranging from 0 to 100 mm (0%-100%) perpendicularly with a
secondary intersecting line that presented best the subjective severity (0%
[better, than normal] to 100% [cannot be worse]). A perpendicular line at
0 mm, baseline (B), represented “asymptomatic/normal” and at 100 mm
represented either “ataxia so severe dog is unable to walk” or “sedation to
the extent dog only sleeps” or “QoL is so poor euthanasia is requested,”
respectively. The length from 0 to the perpendicular line in mm was com-
pared between periods and expressed as a percentage value (0%-100%,
negative = improvement, positive = deterioration).
3.2 | Owner-based epilepsy disease-specific
quality of life aspects (EpiQoL)
In addition to the QoL VAS, the impact from dietary supplementation
on epilepsy and its treatment on the QoL of the dogs and their
owners was assessed at the end of each dietary intervention period. A
questionnaire based on the carer's perception of their dogs and their
own QoL (epilepsy disease-specific quality of life list of key questions
= EpiQoL) was used to study QoL aspects and adverse effect profiles
associated with MCT-DS use.17,18
3.3 | Ketone body measurements
Preprandial and postprandial BHB concentrations were analyzed on
each visit day (V1-V3). Preprandial blood samples were collected at ini-
tial presentation in the morning after fasting for at least 12 hours. Post-
prandial samples were taken 2 hours after consumption of their usual diet
including the prescribed amount of DS per period. Both samples were
stored using clotting activator dipotassium ethylenediaminetetraacetic
acid-containing (with serum-separation gel) polypropylene blood-collection
tubes and plain polypropylene blood-collection tubes (International Scien-
tific Supplies Ltd, Bradford, UK). Blood samples were allowed to clot and
shipped for subsequent analysis for BHB concentrations at 1 of the local
laboratories (Diagnostic Laboratory Services, RVC, UK; IDEXX Laborato-
ries, Inc., Ludwigsburg, Germany).
3.4 | Adverse events and concomitant treatments
Any adverse, abnormal, or both events occurring after enrolment were
reported to the investigator and documented (Table S1). Seizure
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occurrences throughout the study were not classified as adverse events.
Concomitant treatments administered throughout the study were
recorded detailing indication, products used and strength, dose and length
of treatments administered (Table S2). Concomitant changes of ASD
medication or dosages throughout the study led to study exclusion.
3.5 | Statistical analysis
Seizure frequency, defined as the number of seizures per month, and
seizure day frequency, defined as the number of days in which seizures
occurred within a month, were compared between DS periods. Mono-
variate comparisons between the MCT-DS and control DS groups were
conducted using match-paired Student's t tests for parametric data and
Wilcoxon matched-pairs signed rank test for nonparametric data
(GraphPad Prism; STATCON GmbH, Witzenhausen, Germany). The
presence of cluster seizures was compared between DS periods using
the McNemar test. The relationship between 2 continuous variables, such as
seizure frequency and body weight, were analyzed using Pearson's correla-
tion coefficient analysis. All comparisons were 2-sided, and P < .05 was con-
sidered significant. Nonparametric data are presented as median (25th to
75th percentile), and parametric data are represented as mean values and
SD values. Considering potential-fixed (type of DS) and random effects
(treatment order, study center location) of the study design on seizure occur-
rence a multivariate analysis was performed using a linear mixed model.
4 | RESULTS
4.1 | Study population
The study protocol was completed by 28 of the 36 recruited dogs, which
included 18 different breeds at 5 different study sides in 3 different
countries (UK [RVC, N = 12, 43% and Pride Veterinary Centre, N = 4,
14%], Germany [Tierarztpraxis Dr. A. Bathen-Nöthen, N = 4, 14%; Uni-
versity of Veterinary Medicine Hannover, N = 3, 11%; and Tierarztpraxis
Strassenheim, N = 4, 14%], and Finland [University of Helsinki, N = 1,
4%]). One dog of each of the following breeds were included unless oth-
erwise specified: Australian shepherd, Basset Griffon Vendeen (Petit),
Bernese Mountain dog, Border Collie (N = 3), Border Terrier, Cairn Ter-
rier, Chihuahua, Cross breeds (N = 8), Dogue de Bordeaux, German shep-
herd, golden retriever, Hungarian Vizsla, Keeshond, Labrador retriever,
Samoyed (N = 2), Slovakian Rough Haired Pointer, Staffordshire Bull Ter-
rier, Whippet (Table S3). The study population consisted of 16 males, of
which were 12 neutered and 4 were intact, and 12 females, of which
10 were neutered and 2 intact. The population of dogs was on average
5.46 ± 2.61 years of age and weighed 25.6 ± 13.4 kg at start of trial.
4.2 | Antiseizure medication regimes
All 28 dogs were drug resistant to at least 1 of the ASD given and
defined as partial ASD-nonresponders with less than 50% reduction in
seizure frequency. Two dogs received imepitoin only, the rest were
under chronic ASD combination treatment (N = 26; Table S4). Thirty-
two percent (N = 9) of the 28 dogs received a second and 61%
(N = 17) a third ASD. Twenty-five (89%) of the 28 dogs received PB
as ASD. The predominant combination treatment in 40% of the cases
was PB, KBr, and levetiracetam (LEV; N = 14). For the acute treatment
of cluster seizures, 12 owners used rectal diazepam of which 3 owners
also used LEV as pulse treatment. No alterations occurred for the
acute or chronic drug treatment regimens between the control or
MCT-DS period.
4.3 | Main dietary regime and dietary
supplementation
The majority of dogs (82%, N = 19) were fed dry food as a single diet
(46%) or in combination with wet food (11%), raw feed (14%), or
home-cooked feed (11%). The remaining 18% were fed self-cooked
food or raw feed. Independent of the predominant feeding type,
chicken was in 50% of all dogs (N = 14), the main source of meat,
followed by beef (29%), salmon (20%), and lamb (14%). Cereals
(N = 12 [43%], wheat, maize, rice, soya), potatoes (N = 6, 22%), other
vegetables (N = 8 [29%], peas, carrots), or fruits (N = 2, 8%) were
other main components in their feed. In 68% (N = 19) of participating
dogs, it was possible to calculate an average dry matter (DM)-based
composition of the baseline diet from company provided analytical
data mirroring a low fat and low protein diet (crude protein 21.8%,
crude fat 11.75%, crude fibers 3.9%, crude ash 5.96%, calcium 1.18%,
phosphorus 0.78%) (Table S5). While 5 dogs (18%) were on a veteri-
nary prescription diet with low-fat content (<12% crude fat in 100 g
DM), only 2 dogs were fed complete carbohydrate-free regime with
raw meat only. Fifteen out of 28 dogs received as first DS the control-
DS, while 14 got the MCT-DS first, subsequently followed by the
other DS at crossover. The average administered oil amount was
7.03 ± 2.68 mL of MCT-DS or 7.01 ± 2.69 mL of control-DS split into
2 portions a day.
4.4 | Effects on seizure frequency, seizure day
frequency, and severity of seizures
Seizure frequency was significantly lower when dogs were fed MCT-
DS (median 2.51/month, 0-6.67/month) in comparison with the
control-DS (2.67/month, 0-10.45/month; P = .02, Figure 2). During the
MCT-DS period, 2 dogs achieved were seizure free (100% reduction),
3 dogs had a 50% or greater reduction in seizure frequency (58%, 50%-
66%) and 12 dogs had an overall reduction in seizure frequency (21%;
6%-42%). Eleven dogs showed no response to MCT-DS with no change
(N = 3) or an overall increase in seizure frequency per month (N = 8,
8%; 2%-33%) during this period (Table S6).
Seizure day frequency was also significantly lower when dogs
were on the MCT-DS (1.68/month, 0-5.60/month versus 1.99/month,
0-7.42/month, P = .01, Figure 2) with over 75% of the trial population
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achieving reduction in seizure days during this period. During the
MCT-DS period 2 dogs were free of seizures (100% reduction) and
15 dogs had an overall reduction (24%, 11%-40%) in seizure day fre-
quency. In comparison, under control-DS none of the dogs were sei-
zure free or had an overall reduction of more than 50%, but 17 dogs
(61%) had an increase of seizure frequency. Eleven dogs showed no
response to MCT-DS with either no change (N = 5) or an overall
increase in days per month with seizure occurrence (N = 6, 33%,
15%-42%). More than 1 seizure in a day was reported in 75% of the
study population during the control-DS period and only 57% of the
study population during the MCT-DS period (McNemar, P = 0.06), but
this was not significantly different. No other associations were identi-
fied (Table S7).
Potential biases such as treatment order (MCT—control, control—
MCT) or the effect of the study center were considered in mono-
variate comparison and multivariate statistical mixed model.
On monovariate comparison, the average reduction rate in sei-
zure frequency appeared not significantly different for treatment
order or study center; and no association of the supplementation
group with treatment order (r = .1793, X2 = 0.03216, P = .36) or study
center (r = 0.1629, X2 = 0.02653, P = .41) has been identified.
Using the type of DS as fixed and treatment order and study location
as random effects in a multivariate analysis as linear mixed model, seizure
frequency (P = .02) and seizure day frequency (P = .01) appeared signifi-
cantly reduced during MCT treatment period compared to control.
4.5 | Effects on body weight, serum antiepileptic
drug concentration, CBC, clinical chemistry, and blood
ketone concentrations
There was a significant reduction in serum concentrations of PB dur-
ing MCT-DS consumption when compared to the control-DS period
(30.04 ± 7.81 [13.1-44.3] g/mL versus 32.78 ± 7.91 [17.3-49.2] g/mL,
P = .01). Alkaline phosphatase activity was also lowered during the
MCT-DS study period (163.5 U/L [83.25-1578] versus 185.5 U/L
[97.5-2541], P = .03). However, KBr serum concentrations (1.706
± 0.45 mg/mL [0.66-2.54] versus 1.728 ± 0.59 mg/mL [0.59-2.66],
P = .79), pancreas lipase activity (90 μg/mL [30-146.3] versus 83.5 μg/
mL [30-150.8]), and weight (26.79 ± 13.32 versus 26.47 ± 13.16 kg,
P = .98) were not significantly different between control-DS and
MCT-DS periods, respectively.
There were significantly higher concentrations of BHB in both
pre and postprandial blood samples during the MCT-DS period when
compared to the control-DS period (preprandial: 0.07 ± 0.055 versus
0.06 ± 0.048 mmoL/L [P = .03]; postprandial: 0.059 ± 0.037 versus
0.049 ± 0.028 mmoL/L [P = .01]), respectively. However, the differ-
ences between preprandial and postprandial BHB blood concentra-
tions within DS periods were not significantly different ([ΔMCT-DS:
0.01 versus Δcontrol-DS: 0.01] mmol/L; P = .67). All other CBC, bio-
chemistry, glucose, and bile acids stimulation results were not signifi-
cantly different between the DS groups.
4.6 | Effects on VAS and adverse effect profiles
of antiepileptic drug medication
There were significant differences in the VAS compared to baseline.
During the MCT-DS period it was reported that dogs were less
sedated (B: 47% ± 28% versus MCT: 29%±18%, P = .002), less ataxic
(B: 43% ± 28% versus MCT: 29% ± 25%, P = .003) than baseline and
had an overall better owner reported QoL (B: 38% ± 21% versus
MCT: 10% ± 14%, P ≤ .001). Apart of sedation (B: 47% ± 28% versus
control [C]: 29% ± 21, P = .007), there were no other significant differ-
ences in VAS comparisons between MCT and control-DS or both with
baseline (Figure 3).
F IGURE 2 Effect of the medium-chain
triglyceride dietary supplement (MCT-DS, light
pointed) on: A, seizure frequencies per month
and, B, seizure days per month compared with the
control dietary supplement (control-DS, dark-gray;
N = 28). Significant reductions in the A, number of
seizures per month (P = .02) and B, seizure days
per month (P = .02) during the MCT-DS phase in
comparison with the control-DS was found. Data
are shown as box-and-whisker plots (central lines
of the box represent the median, lower, and upper
limits of the box represent the 25th and 75th
percentiles and whiskers represent the minimum
and maximum). Two-sided Wilcoxon's matched-
pairs' rank tests were used to compare control and
MCT-DS groups. *P < .05
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Similarly, in the EpiQoL questionnaire, the owner's perceptions
between both dietary periods (MCT-DS, control-DS) and the baseline
(B) have been compared. Owners reported that during the MCT-DS
study period they were less “bothered” by their dog's mental status
(1-5 [not at all bothersome-extremely bothersome], B: 2 [1-5] versus
MCT: 2 [1-2], P = .03) and that their dog had a less severely ataxic gait
(1-5 [very mild-very severe]; B: 3 [1-4]versus MCT: 2 [1-3], P = .003;
C: 3 [2-4 ]versus MCT: 2 [1-3], P = .002). In addition, the owners
reported that they better tolerated the ASD adverse effects seen in
their dogs (1-5 [strongly agree-strongly disagree]; B: 3 [2-4] versus
MCT: 2 [1-3], P = .004; C: 3 [3-4] versus MCT: 2 [1-3], P = .003) than
before or in comparison to the control oil.
4.7 | Adverse events and disease-related death
Observation about any unfavorable, unintended health abnormality
occurred after enrolment, regardless it was considered as MCT-DS- or
control DS-related event, was reported to the investigator and docu-
mented (Table S1). Independent of the administered DS, no adverse
event occurred more than once during 1 dietary period or was predomi-
nantly found associated to the type of DS. Seizure occurrences and
disease-related death throughout the study were not classified as adverse
events and considered as sudden unexpected death in epilepsy.6,35,46
4.8 | Withdrawn and excluded dogs
Eight further dogs were recruited but did not complete the study, of
which 2 were excluded at visit 1 prior to DS allocation. One dog had a
significant increase in canine pancreatic lipase activity, while the other
dog received chronic administration of cannabidiol. Furthermore, 1 dog
was excluded after completion of the trial and 5 were withdrawn during
the trial. For the dogs which withdrew, 2 dogs were on the MCT-DS
period and 4 were on the control-DS period at time of withdrawal. Two
dogs, withdrawn during the MCT-DS period, were euthanized before
study completion due to uncontrollable cluster seizures and owner-
directed postictal aggression. On the other hand, 2 dogs were eutha-
nized due to uncontrollable cluster seizures or status epilepticus during
the control-DS period. One dog was withdrawn, during the control-DS
period, as the owner requested to alter their ASD treatment due to
uncontrollable cluster seizures. One dog was excluded from subsequent
data analysis after completion of the trial as this dog had been diag-
nosed with pulmonary hypertension and dilatative cardiomyopathy,
from which alterations in ASD clearance and elimination were expected
due to chronic furosemide consumption.
5 | DISCUSSION
The objective of this clinical trial was to evaluate the antiseizure effi-
cacy and tolerability of an MCT oil in dogs with IE chronically treated
with standard ASDs. Twenty-eight dogs with epilepsy were included
in the 6-month randomized, placebo-controlled, crossover prospective
trial. The supplementation of commercially available MCT oil, con-
taining C10 and C8, to a stable, individually variable base diet was well
tolerated and decreased both seizure frequency and seizure day fre-
quency compared to control oil (Figure 4).
Epidemiological studies suggest differences between the intrinsic
severity of epilepsy among individuals linked to their response to
medication and the long-term therapeutic success. In addition, individ-
ual seizure-associated alteration on pharmacodynamics and kinetics
F IGURE 3 Effects of the medium-chain
triglyceride dietary supplement (MCT-DS) on
ataxic gait, sedation and quality of life (QoL).
Visual analog score was compared per dietary
supplementation period to baseline records at
enrolment visit to assess antiseizure drug-related
adverse effect profiles in the course of the trial.
The owner was asked to draw a secondary
intersecting line perpendicular to the line of
measurement that best represented the subjective
severity (0 [better, than normal] to 100% [cannot
be worse]). The figure shows the owner reported
perception and in percentage normalized grading
of each aspect illustrated in a column bar graph.
The MCT-DS intake resulted in significant
improvement of ataxia (P = .003), sedation
(P = .002), and QoL (P = <.001) of the
population (N = 28)
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of ASD has been discussed.47 This might explain that in human
patients only around 10% of the overall cohort are seizure free when
a 2nd ASD is added to the treatment and less than 4% for any addi-
tional ASD given.48 Some veterinary studies report an even lower sei-
zure freedom when a 2nd or 3rd ASD is given.49 When more than
50% reduction in seizure frequency is used as definition of ASD
response, usually a third of the reported population in the literature
will respond to the 2nd ASD.8,10,50 In the current study, all 28 dogs in
this trial were classified as resistant to at least 1 ASD and suffered
from at least 1 seizure per month at trial start. Two dogs received
1 ASD (impetoin), while most dogs were on 2 (N = 9) or 3 drugs
(N = 17) as antiseizure combination therapy. The overall reduction in
seizure frequency between treatment groups was small and that only
a small cohort of animals was seizure free or had more than 50%
reduction in seizure frequency. Two dogs achieved seizure freedom,
3 additional dogs had ≥50% and 12 had <50% reductions in seizure
frequency and 11 dogs showed no change or an increase in seizure
frequency. The response to MCT treatment was better in the study
reported by Law et al24 with 14% becoming seizure free and 48% of
the dogs having more than 50% reduction in seizure frequency. In
both studies MCTs were very well tolerated and in the current study
even an improvement is the ASD adverse-effect profile was noted.
Owner-reported improved level of sedation and ataxia and perceived
QoL during the MCT-DS period compared to baseline. This could be
at least in parts explained by a small but significant reduction in PB
serum concentrations when dogs were on the MCT-DS. There were
no significant differences in body weight, bile acids, cholesterol, pan-
creatic lipase activity, glucose, and KBr serum concentrations between
MCT-DS and control DS periods. MCT-DS as dietary management
appears safe and might be considered as an option for some
individual dogs.
Consumption of the MCT-DS reduced PB serum concentrations
by approximately 8% and reduced liver enzyme alkaline phosphatase
activity by 10% when compared to the control-DS. Similar results
were not observed when dogs with IE were fed a complete kibble diet
enriched with MCTs.24,38 The pharmacokinetic properties of ASDs
have been shown to be influenced by other medications,51 diets,52-57
or both, whereby interactions might manifest via amplification of liver
metabolism. Maguire et al showed in 2000 that dietary protein, fat, or
both restriction led to significantly decreased volume of distribution
and half-life, and increased clearance and elimination rates of PB.57 It
is of interest to note that a fat- and protein-restricted diet resulted in
increased serum alkaline phophatase activity.57 The results presented
in this study show that MCT oil and its respective metabolic constitu-
ents may also affect the absorption and excretion rates of PB.58,59
Furthermore, it has been demonstrated that PB, when consumed with
food, is not absorbed as well as in a fasting state and decreases the
bioavailability.54 MCT oil-induced perturbations on PB absorption
could lead to decreased liver enzyme activity, such as alkaline phos-
phatase activity, and partly improved adverse effect profiles.7,60
F IGURE 4 Trial diet composition: the figure summarizes the distribution of the different main feeding regimes within the study population
(N = 28). The in average calculated oil amount based on 9% of the ME requirement was 7.03 (SD 2.68) mL of MCT-DS or 7.01 (SD 2.69) mL of
control-DS split into 2 portions a day added to the base diet. The oil amount was calculated from the patients metabolic energy requirement
derived from the metabolic body weight (RER = 70 [10 kg]3/4, ME = RER × factor, life stages corresponding factors used to estimate daily energy
needs for dogs). DF, dry food; HCF, home-cooked food; MBW, metabolic body weight; MCT-DS, medium-chain triglyceride dietary supplement;
ME, metabolic energy; RER, resting energy requirement; RW, raw food; WF, wet food
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PB induces the expression of cytochrome P450 genes and
increase liver enzyme activities,61-63 and CYP152 family P450s to oxi-
datively decarboxylate fatty acids and induce expression levels.64
MCT are metabolized by some CYP4 isoforms, which is a family of
P450 enzymes.65 The reduced PB concentration associated with
reduced alkaline phosphatase enzyme activities might therefrom also
result from MCT provoked higher cytochrome p450 activities in the
liver.66 Further in vitro studies are needed to confirm this observation
and link it to potential metabolic pathways.
Although PB serum concentrations were significantly lower dur-
ing MCT consumption, the relative reduction might or might not be
clinically relevant for the improvements in both seizure control or
owner-perceived adverse effects shown in this study.67,68 The supple-
mentation of MCT oil described in this trial resulted in a significant
reduction of ASD adverse effects, which has not been previously
reported. Owners reported an improvement in ataxia and sedation
which mighty have contributed to owners also thinking that their
dog's QoL has improved during the MCT-DS period compared to
baseline. These changes suggest a better tolerability of ASD. Anti-
epileptic and aforementioned pharmacokinetic properties of MCT oil
supplementation may act in a synergistic manner, leading to less
adverse effects for epileptic dogs with improved seizure control.
Preprandial and postprandial blood BHB concentrations were
both significantly elevated in this trial, when dogs consumed the
MCT-DS in comparison to the control-DS, which is in accordance with
dogs fed an MCT-enriched kibble diet.24 In a Drosophila invitro model,
BHB reduces seizure-like neuronal activity, which is thought to be
mediated via KATP channel activity and GABAB signaling inhibition.
69
In a kainic acid rat seizure model intraperitoneal BHB administration
prolonged the onset of induced seizures. In addition, neuronal cell
death was alleviated and linked to protective effects.70 More recent
in vitro studies also suggest that BHB exerts beneficial neuro-
protective functions by way of gene regulation and promotion of
brain-derived neurotrophic factor expression.71 Other than seizure
suppressing effects, elevated blood BHB concentrations have anxio-
lytic effects in lab rats.72 In humans receiving a ketogenic diet (KD),
the increase in blood BHB concentrations and other ketone bodies is
considered to play a crucial role for improved seizure control.28,30,73
Here, the majority of dogs received over 50% of their daily calorie
intake from carbohydrates (nitrogen-free extract: 56.59%; from
cereals, potatoes, or other vegetables), fat (11.75%), and protein
(21.8%). This macronutrient profile is in contradiction to the common
KDs in human medicine which are usually of a high-fat, low-
carbohydrate composition.74 Therefrom, the results of this study dem-
onstrate also that MCT supplementation with a non-KD base diet can
enhance BHB production. However, the dogs did not become ketotic,
as observed in humans under KD diet. Accordingly, it might be sug-
gestive that the rapid onset of antiseizure properties in dogs consum-
ing the MCT-DS might be governed more by the direct effect of
certain MCTs, rather than the downstream metabolites of BHB.
The MCT-enriched kibble diet reported by Law et al in 2015 con-
tained medium-chain fatty acids C8, C10, and C12 which was the only
compositional difference to the control diet.24 C10 not only acts as a
noncompetitive AMPA receptor antagonist resulting in direct inhibi-
tion of excitatory neurotransmission, and thus exerts an anticonvul-
sant effect,75 but also has synergistic effects with a newly introduced
ASD in human medicine.76 Furthermore, C10 on its own might be able
to modulate mitochondrial proliferation via PPARγ receptor77 and
improve brain mitochondrial energy homeostasis in a dose-dependent
manner.78 An enhanced anticonvulsant effect is observed in mice
under seizure provocation by intravenous administrated pentylenetet-
razol, when C10 and C8 was orally coadministered.79 In multiple vitro
seizure and status epilepticus models, the inactive unbranched com-
pound C8 does not to play a direct role in provoking antiepileptic
properties.80,81 However, methyl-branched derivatives of C8 enhance
seizure control and neuroprotection.82 Thus far, the available scien-
tific evidence indicates that C10 may be more relevant than C8 with
regard to active interaction with cellular targets that can explain anti-
seizure effects from MCT consumption.31,83,84
The dogs' baseline diets in this study have not been controlled to
ensure a balanced nutrient supply as they varied between the trial
participants and therefore must be considered a limitation of this diet
trial study. In addition, the original MCT content cannot be evaluated
in the baseline diet. However, the dietary access to MCTs is limited in
the usual diet of dogs. Average sources used in production of com-
mercial foods or the composition of a home-made or raw-feed nor-
mally contain relatively low concentrations or no MCTs.85,86 In
commercial pet food, MCTs are typically not added to diets due to
reports on decreased food palatability.87 Therefrom, a negligible
impact on the results of the baseline on this trial could be expected.
Likewise, because MCTs are so rarely used in commercial pet food, its
supplementation or integration may easily offer more options to man-
age chronic neurological diseases and should be explored further in
the future.
The oral tolerability of MCTs in dogs has been widely explored
with controversial findings and the occurrence of gastrointestinal
signs or palatability issues were more likely.87-91 The percentage of
metabolic energy chosen as amount of MCT-DS was orientated on
the previous study from Law et al in 2015, but also tolerance and pal-
atability findings from other studies,87-91 but also recommendation to
meet nutritional guidelines established by the Association of American
Feed Control Officials and the National Research Council.92 In this
trial, adverse events have not been found in higher frequency or pre-
dominantly associated to 1 type of DS in this trial. Thus, the seen
adverse events were considered as not provoked by the dietary inter-
ventions of this study and as naturally occurring diseases.
One relevant limitation of this clinical study could be the study
center effect. However, as the number in each of the centers was
rather small and each dog experienced at each visit the same scenario,
a center effect was expected to be small and was not identified on
statistical analysis. We were also not able to identify a treatment
order bias. In addition, the findings of the current trial confirm earlier
findings in a single center study.24 Another limitation of the analysis
was that an intention to treat analysis (ITTA) was not conducted. Nor-
mally, ITTA is an analysis approach in which all recruited patients are
evaluated as block randomized, regardless of the dietary intervention
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they actually received.93 However, as in randomized clinical trial with
epileptic patients, the dropout rate appears to be higher, especially in
the beginning, all of the 8 dogs dropped out in the first leg of the
study. Therefore, an ITTA would not be appropriate.
In summary, this trial provides additional evidence for the use of
MCT oil as a DS to a stable base diet as a potential therapeutic man-
agement option for dogs with epilepsy. Although the overall signifi-
cant statistical effect was small, some dogs had a good response.
Future studies are needed to test, if MCT can be clinically more signif-
icant in drug-naive dogs or dogs with less drug-resistant epilepsy. The
result presented by this study further emphasizes the potential impli-
cations of dietary management for both human and canine drug-
resistant epilepsy. The effectiveness and efficacy of the MCTs on epi-
lepsy should be further investigated involving a pragmatic approach
with larger longer-lasting randomized controlled trials and inclusion of
an intention-to-treat analysis.
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